333 related articles for article (PubMed ID: 27166503)
1. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
Bockorny B; Pectasides E
Future Oncol; 2016 Aug; 12(15):1833-46. PubMed ID: 27166503
[TBL] [Abstract][Full Text] [Related]
2. Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma.
Pectasides E
Clin Ther; 2016 Jul; 38(7):1589-99. PubMed ID: 27041412
[TBL] [Abstract][Full Text] [Related]
3. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
4. Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature.
de la Fouchardiere C; Decoster L; Samalin E; Terret C; Kenis C; Droz JP; Coutzac C; Smyth E
Cancer Treat Rev; 2021 Nov; 100():102289. PubMed ID: 34583303
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature.
Kamposioras K; Ntellas P; Nikolaou M; Germetaki T; Gazouli I; Dadouli K; Zarkavelis G; Amylidi AL; Tolia M; Mauri D
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926989
[TBL] [Abstract][Full Text] [Related]
6. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Kaur A; Dasanu CA
Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer.
Murphy AG; Kelly RJ
Hematol Oncol Clin North Am; 2017 Jun; 31(3):485-498. PubMed ID: 28501089
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic Therapy in Gastroesophageal Cancer.
Jin Z; Yoon HH
Hematol Oncol Clin North Am; 2017 Jun; 31(3):499-510. PubMed ID: 28501090
[TBL] [Abstract][Full Text] [Related]
9. [Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies].
Vrána D; Matzenauer M; Melichar B
Klin Onkol; 2017; 31(1):35-39. PubMed ID: 29488776
[TBL] [Abstract][Full Text] [Related]
10. Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma.
Anandappa G; Chau I
Hematol Oncol Clin North Am; 2017 Jun; 31(3):529-544. PubMed ID: 28501092
[TBL] [Abstract][Full Text] [Related]
11. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A; Park R; Sun W
J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
[TBL] [Abstract][Full Text] [Related]
12. Update on metastatic gastric and esophageal cancers.
Shah MA
J Clin Oncol; 2015 Jun; 33(16):1760-9. PubMed ID: 25918288
[TBL] [Abstract][Full Text] [Related]
13. Gastric and gastro-oesophageal cancer therapy.
Das P; Ajani JA
Expert Opin Pharmacother; 2005 Dec; 6(16):2805-12. PubMed ID: 16318431
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
15. Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.
Cetin B; Wabl CA; Gumusay O
Immunotherapy; 2023 Aug; 15(12):945-962. PubMed ID: 37291863
[TBL] [Abstract][Full Text] [Related]
16. Optimal management of gastroesophageal junction cancer.
Greally M; Agarwal R; Ilson DH
Cancer; 2019 Jun; 125(12):1990-2001. PubMed ID: 30973648
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
18. Role of chemotherapy in the treatment of gastroesophageal cancers.
Hwang JJ
Oncology (Williston Park); 2007 Apr; 21(5):579-86; discussion 587, 591-2. PubMed ID: 17536343
[TBL] [Abstract][Full Text] [Related]
19. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
van Velzen MJM; Derks S; van Grieken NCT; Haj Mohammad N; van Laarhoven HWM
Cancer Treat Rev; 2020 Jun; 86():102024. PubMed ID: 32388292
[TBL] [Abstract][Full Text] [Related]
20. [Potentiality of Immune Checkpoint Inhibitors for Advanced Esophageal and Gastric Cancer].
Muro K
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1041-7. PubMed ID: 27628545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]